Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (1070)	10/12/1998 6:48:00 PM
From: Chuca Marsh	Read Replies (1) \| Respond to of 1501

A Rec'er or is it spelt..wrecker ( Just joking but it is strange that if you look at the Chart on 7 July...the MAIN downturn in Share Price happened right after this 7 July NR then....beware the Ides of July! And Augusta Ceasar - not to mention this Dam October Fest! As the song says, see you in Second Quarter of 1999...Ides of '99??? ?)( Serve no worm- befor its time.: Inflazyme Pharmaceuticals Ltd - Fagan says drug company undervalued Inflazyme Pharmaceuticals Ltd IZP Shares issued 24,997,493 1998-08-10 close $0.77 Monday Aug 10 1998 Brian Fagan, writing in the August 1998 edition of the Fagan Report, says Inflazyme Pharmaceuticals is a buy at the July 31 price of 78 cents. Mr. Fagan recommended Vancouver-based Inflazyme last month at 86 cents. The letter writer says that while a scientific understanding of drug developers among investors is both impossible and unnecessary, investors can judge these companies by the stature of the people behind them, and the letter writer believes Inflazyme has such people. Mr. Fagan notes that development and licensing of individual drugs take four or five years -- possibly much longer. Clinical trials for Inflazyme's IPL-576 compound are scheduled for the second quarter of 1999. Referring to IPL-576, Mr. Fagan says: "In comparing its market cap and potential to other biotechs, (Inflazyme) appears to be undervalued at its stage of development." He says his buy recommendation still applies. Market imbalances may create further buying and selling opportunities over the next two years, Mr. Fagan adds. Inflazyme Pharmaceuticals Ltd - Fagan says biotech company a buy near 52-week low Inflazyme Pharmaceuticals Ltd IZP Shares issued 24,997,493 1998-07-07 close $0.74 Tuesday Jul 7 1998 Brian Fagan, writing in the July 1998 edition of the Fagan Report, says Inflazyme Pharmaceuticals is a buy at 86 cents. Inflazeme is trading near its 52-week low of 71 cents, he notes, down from $2.60. The company has $8-million in working capital, as well as more than 50 proprietary and patented compounds designed to combat a wide range of inflammatory diseases, Mr. Fagan says. The inflammatory market is about $28-billion annually. Inflazeme's lead compound is IPL-576, which is targeted at the $6-billion asthma market. Major investors such as Goldman Sachs have done due diligence on Inflazeme and participated in a $6-million private placement at 85 cents. canada-stockwatch.com Devavue-been three done read that in the Firsh Honalululul Report, Dallass Texas Report, Florida New wave Stock reporter, Neil Madashell Pro- Trader and Mini Zap Analyst Report. Now, the Fagan Report. Mine Irish Eyes Are Shining ...I skinned my Shinns while on my knees. So, My Eyes are Shinning on my knees at Wounded Heart. I left my Heart at Wounded Knee. A tear drops in my eye, and what do I see. Samo. Breath is important, congested lungs are important and the good that could of been planned on the correct tract...IS IMPORTANT! Time to change from SAMO tract. Sam Walton- the Number One Retailer/next to IZP. Chuca